Article Information
History
- January 4, 2022.
Article Versions
- Version 1 (January 1, 2022 - 14:48).
- You are currently viewing Version 2 of this article (January 4, 2022 - 10:18).
- Version 3 (January 12, 2022 - 11:30).
- View Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Paul A. Christensen*,†,‡,§,
- Randall J. Olsen*,†,‡,§,
- S. Wesley Long*,†,‡,§,
- Richard Snehal†,
- James J. Davis¶,**,
- Matthew Ojeda Saavedra†,
- Kristina Reppond†,
- Madison N. Shyer†,
- Jessica Cambric†,
- Ryan Gadd†,
- Rashi M. Thakur†,
- Akanksha Batajoo†,
- Regan Mangham†,
- Sindy Pena†,
- Trina Trinh†,
- Jacob C. Kinskey†,
- Guy Williams†,
- Robert Olson¶,**,
- Jimmy Gollihar‡ and
- James M. Musser†,‡,§,††
- †Laboratory of Human Molecular and Translational Human Infectious Diseases, Houston Methodist Research Institute and Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas
- ‡Laboratory of Antibody Discovery and Accelerated Protein Therapeutics, Center for Infectious Diseases, Houston Methodist Research Institute and Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas
- §Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York
- ¶Consortium for Advanced Science and Engineering, University of Chicago, Chicago, Illinois
- **Computing, Environment and Life Sciences, Argonne National Laboratory, Lemont, Illinois
- ↵††Address correspondence to James M. Musser, M.D., Ph.D., Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, 6565 Fannin Street, Suite B490, Houston, Texas 77030. Tel: 713.441.5890, E-mail: jmmusser{at}houstonmethodist.org
↵* Contributed equally
Posted January 04, 2022.
Early signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with COVID-19 caused by the Omicron variant of SARS-CoV-2 in Houston, Texas
